The city of Philadelphia, Pennsylvania, currently has 13 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/15/2024
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis